Abstract
Background Pulmonary hypertension (PH) is common in advanced heart failure which exhibits short-term improvement after left ventricular assist device (VAD) implantation or orthotopic heart transplantation (OHT), but long-term effects remain unknown. This study evaluated PH persistence after VAD as destination therapy (VAD-DT), bridge to transplant (VAD-BTT), or OHT-alone.
Methods A retrospective review of patients who underwent VAD-DT (n=164), VAD-BTT (n=111), or OHT-alone (n= 138) at a single tertiary-care center. Right heart catheterization (RHC) data was collected pre-, post-intervention (VAD and/or OHT), and 1-year from final intervention (latest-RHC) to evaluate the longitudinal hemodynamic course of right ventricular (RV) function and PH. PH (Group-II and Group-I) definitions were adapted from expert guidelines.
Results All groups showed significant improvements in mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure (PAWP), cardiac output (CO), and pulmonary vascular resistance (PVR) at each RHC with greatest improvement at post-intervention RHC (Post-VAD or Post-OHT). PH proportion reduced from 98% to 26% in VAD-BTT, 92% to 49% VAD-DT, and 76% to 28% from pre-intervention to latest-RHC. At latest-RHC mPAP remained elevated in all groups despite normalization of PAWP and PVR. VAD-supported patients exhibited suppressed pulmonary artery pulsatility index (PaPi< 3.7) with improvement only post-transplant at latest-RHC alongside improved right atrial pressures (RAP). Furthermore, post-transplant with PH at latest-RHC (n=60) exhibited lower survival (HR: 2.1 [95%CI: 1.3-3.4], p<0.001).
Conclusion Despite an overall significant improvement in pulmonary pressures and PH proportion, a notable subset of patients exhibited residual RV derangements and PH persistence post-intervention. This post-intervention PH impacted post-transplant survival.
Condensed Abstract This study evaluates the longitudinal hemodynamic course of right ventricular (RV) function associated with heart-failure-related Pulmonary Hypertension (PH) and the impact of advanced interventions such as ventricular assist device and/or orthotopic heart transplant on PH persistence. Patients undergoing advanced interventions exhibit differences in PH prevalence which are dependent on the intervention received. Our results highlight despite an overall improvement in pulmonary pressures and PH, a notable number of patients exhibit RV dysfunction consistent with persistent PH. Furthermore, the persistence of PH after successful cardiac transplantation in a subset of patients continues to impact mortality in the long-term.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Al Ghouleh received research support from the National Institutes of Health (R01HL148712-01), American Heart Association (AHA Scientist Development Grant, grant # 15SDG24910003), American Lung Association (American Lung Association Biomedical Research Grant, grant # RG-515656) and Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension. Dr. Rajaratnam received support from the Ruth L. Kirschstein National Research Service Award (T32 HL-110849-09). Dr. Shah received support from the National Institutes of Health(5K23GM122069). VMI researchers receive support from Vitalant and the Hemophilia Center of Western Pennsylvania.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional Review Board at the University of Pittsburgh gave ethical approval for this work (STUDY20090170).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sources of Funding: Dr. Al Ghouleh received research support from the National Institutes of Health (R01HL148712-01), American Heart Association (AHA Scientist Development Grant, grant # 15SDG24910003), American Lung Association (American Lung Association Biomedical Research Grant, grant # RG-515656) and Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension. Dr. Rajaratnam received support from the Ruth L. Kirschstein National Research Service Award (T32 HL-110849-09). Dr. Shah received support from the National Institutes of Health(5K23GM122069). VMI researchers receive support from Vitalant and the Hemophilia Center of Western Pennsylvania.
Disclosures: All authors have no relevant financial or non-financial relationships to disclose.
Data Availability
All non-identifiable, non-personal health information data produced in the present study are available upon reasonable request to the authors.
List of Abbreviations
- PH
- Pulmonary Hypertension
- Cpc-PH
- Combined Post-Capillary Pulmonary Hypertension
- HF
- Heart Failure
- IpcPH
- Isolated Post-Capillary Pulmonary Hypertension
- LV
- Left Ventricle
- OHT
- Orthotopic Heart Transplantation
- PAH
- Pulmonary Arterial Hypertension (Group 1 pulmonary hypertension)
- PH-LHD
- Pulmonary Hypertension in the setting of Left Heart Disease (Group 2 PH)
- RV
- Right Ventricle
